Herpes Zoster Pipeline Therapeutics Assessment 2024 (Updated)

DelveInsight's, "Herpes Zoster Pipeline Insight 2024," report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Herpes Zoster Research. Learn more about our innovative pipeline today! @ Herpes Zoster Pipeline Outlook- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Herpes Zoster Pipeline Report
• In November 2024:- GlaxoSmithKline- A Phase 3a, Observer-blind, Randomized, Controlled Study to Evaluate the Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age. The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
• DelveInsight's Herpes Zoster pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Herpes Zoster treatment.
• The leading Herpes Zoster Companies such as EyeGene, Shulov Innovative Science, Dynavax Technologies, Curevo Vaccine, Vaccitech, NanoViricides, Pfizer, CPL Biologicals, Vapogenix, EuBiologics, Enzolytics, NAL Pharma, Gene One Life Science, Akshaya Bio, Turn therapeutics, AIM Vaccine, XBiotech, HilleVax Inc. and others.
• Promising Herpes Zoster Therapies such as GSK1437173A, mRNA-1468, Shingrix, PED-HZ/su, JCXH-105, Z-1018, VARIVAX, Suduvax, and others

Stay informed about the cutting-edge advancements in Herpes Zoster treatments. Download for updates and be a part of the revolution in care @ Herpes Zoster Clinical Trials Assessment- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Herpes Zoster Emerging Drugs Profile
• CRV-101: Curevo Inc.
CRV-101 is a next-generation shingles vaccine candidate designed to maximize the CMI protection by combining the gE protein antigen with our proprietary adjuvant. Curevo's CRV-101 is an investigational adjuvanted subunit vaccine for the indication of the prevention of Herpes Zoster in older adults. The adjuvanted subunit vaccine strategy contrasts with traditional approaches using live killed or attenuated viruses. Sub-unit vaccines do not contain virus components and cannot cause infection. The adjuvant component was specifically engineered to produce an optional immune response while using a smaller amount of adjuvant with a targeted structure-function approach. CRV101 is being developed in Phase II stage of development to treat Herpes Zoster.

• EG-HZ: EyeGene
A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA05, an adjuvant system which is a non-toxic LOS-derived substance with optimal immunologic activity. A Phase I clinical trial evaluating the EG-HZ vaccine has been completed.

• ZEP-3: Shulov Institute for Science LTD.
SIS is developing several 'NCE's for anti-inflammatory indications. ZEP-3 possess a unique, combination of pharmacological activities for the treatment of these clinical areas of research. The unique combination of anti-inflammatory and anti-viral activity, in addition to analgesic activity, gives ZEP-3 an advantage over the existing treatments for Herpes Labialis, which are only based on anti-viral activity (Zovirax). Efficacy studies have shown that ZEP-3 is equally effective both on HSV-1 and HSV-2 for acyclovir-resistant viruses. At the same time, a growing population does not respond to the existing therapy because of acyclovir resistance. The Company's ZEP-3 is not based on steroids, thus giving the company a clear and unique advantage. SIS completed a Phase I clinical study on healthy volunteers. This Phase I was suitable for several indications such as: Herpes Labialis, Herpes Zoster, Atopic Dermatitis and Burns.

Learn more about Herpes Zoster Drugs opportunities in our groundbreaking Herpes Zoster Research and development projects @ Herpes Zoster Unmet Needs- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Herpes Zoster Companies
EyeGene, Shulov Innovative Science, Dynavax Technologies, Curevo Vaccine, Vaccitech, NanoViricides, Pfizer, CPL Biologicals, Vapogenix, EuBiologics, Enzolytics, NAL Pharma, Gene One Life Science, Akshaya Bio, Turn therapeutics, AIM Vaccine, XBiotech, HilleVax Inc. and others.

Herpes Zoster pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Herpes Zoster Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Herpes Zoster treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Herpes Zoster Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Herpes Zoster Pipeline Report
• Coverage- Global
• Herpes Zoster Companies- EyeGene, Shulov Innovative Science, Dynavax Technologies, Curevo Vaccine, Vaccitech, NanoViricides, Pfizer, CPL Biologicals, Vapogenix, EuBiologics, Enzolytics, NAL Pharma, Gene One Life Science, Akshaya Bio, Turn therapeutics, AIM Vaccine, XBiotech, HilleVax Inc. and others.
• Herpes Zoster Therapies- GSK1437173A, mRNA-1468, Shingrix, PED-HZ/su, JCXH-105, Z-1018, VARIVAX, Suduvax, and others
• Herpes Zoster Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Herpes Zoster Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase II

For a detailed overview of our latest research findings and future plans, read the full details of Herpes Zoster Pipeline on our website @ Herpes Zoster Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/herpes-zoster-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Herpes Zoster: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Herpes Zoster - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CRV1O1: Curevo Vaccine
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. EG-HZ: EyeGene
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. mRNA-1468: Moderna
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Herpes Zoster - Collaborations Assessment- Licensing / Partnering / Funding
21. Herpes Zoster - Unmet Needs
22. Herpes Zoster - Market Drivers and Barriers
23. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.